Dr. Reddys Laboratories Ltd.

Dr Reddy’s Laboratories has launched Clopidogrel Tablets, USP 75mg and 300mg, a bioequivalent generic version of Plavix in the US market. The ANDAs for Clopidogrel Tablets USP 75mg and 300mg are approved by the United States Food & Drug Administration (USFDA). The company is among the first applicants to submit a substantially complete ANDA for Clopidogrel Tablets USP 300mg with a Paragraph IV certification and was awarded 180 days of marketing exclusivity for this strength.

The Plavix brand had US sales of about $6.740 billion for the most recent twelve months ending March 2012. The company’s Clopidogrel Tablets, USP 75mg are available in bottle count size of 30, 90 and 500 while, Clopidogrel Tablets, USP 300mg are available in the blister packs of 30’s counts.

The company registered a growth of 27.68% in fourth quarter ended March 31, 2012 net profit at Rs 211.79 crore as compared to Rs 165.87 crore for the quarter ended March 31, 2011. Total income increased by 49.09% to Rs 2051.18 crore January-March quarter, 2012 from Rs 1375.77 crore for the similar quarter a period ago.